Biocon · NSE: BIOCON · BSE: 532523

Q2 FY22 results · Jul–Sep 2021

Biocon reported revenue from operations of ₹1,840.40 crore (up 5.5% from Q2 FY21) and net profit of ₹159.70 crore (down 18.3% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	1,840.40	1,744.80	+5.5%	1,760.60	+4.5%
Other income	104.90	15.50	+576.8%	47.20	+122.2%
Total income	1,945.30	1,760.30	+10.5%	1,807.80	+7.6%
Profit before share of associates & JVs and tax	256.60	222.70	+15.2%	221.80	+15.7%
Share of profit/(loss) of associates & JVs	(50.60)	0.00		(56.10)
Net profit for the period	159.70	195.40	−18.3%	108.40	+47.3%
Attributable to shareholders of the company	138.30	169.30	−18.3%	—	—
EPS, basic (₹)	1.16	1.43	−18.9%	0.71	+63.4%
Net margin (%)	8.7	11.2		6.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	364.80	560.00	−34.9%	382.70	−4.7%
Other income	40.50	38.40	+5.5%	49.20	−17.7%
Total income	405.30	598.40	−32.3%	431.90	−6.2%
Profit before tax	(9.30)	99.80	Turned loss	46.50	Turned loss
Net profit for the period	(6.60)	95.00	Turned loss	29.10	Turned loss
EPS, basic (₹)	(0.06)	0.80	Turned loss	0.24	Turned loss
Net margin (%)	-1.8	17.0		7.6

Consolidated

Filed with BSE: 22 Oct 2021, 17:48 IST
Board meeting: 21 Oct 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 22 Oct 2021, 17:48 IST
Board meeting: 21 Oct 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE